CMPS
COMPASS PathwaysDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Positive late-stage readouts, constructive FDA interactions, and payer traction could re-rate COMPASS toward analyst upside within 12 months.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +3.4.
What can break
Binary clinical trial/readout failure
Momentum
91
Value
41
Sentiment
21
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.17 · Bull $16.08 · Bear $5.48
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-02-26 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $23.44
Why
Momentum91 · Δ7d +3.4
Value41 · Δ7d -0.1
Sentiment21 · Δ7d +5.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
91
26% active weight
Current posture
7d trendImproving
Δ7d
+3.4
Δ21d
-0.2
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
21
34% active weight
Current posture
7d trendImproving
Δ7d
+5.3
Δ21d
+10.8
Why this grade
Composite grade D. Momentum 90.8 / Value 41.1 / Sentiment 21.1
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$1.67B
Beta
1.93
Shares Out
134.92M
P/E (TTM) · Derived
-4.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-7.94
Rev YoY
-
EPS YoY
+51.4%
Gross Margin
-
Op Margin
-
Net Debt
-$114.95M
Current Ratio
3.32
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology